Mr. Aditya Santoki graduated from Duke University in 2021 cum laude as a Chemistry major. While at Duke, Mr. Santoki was a neurobiology researcher in Dr. Cagla Eroglu’s lab and investigated the rate of neuronal cell death in Huntington’s Disease. Having self-studied computer science in college, Mr. Santoki designed a program that would characterize the rate of neuronal cell delineated by brain region, eventually seeing his work published as a second-author in Cell Reports. Additionally, while at Duke, Mr. Santoki was also deeply involved in health policy research. After having taken an Introduction to the U.S. Healthcare System class with Dr. Nathan Boucher, Mr. Santoki designed an independent project to assess the determinants of vaccine hesitancy in Durham County. As a part of his project, Mr. Santoki interviewed physicians and patients to find that even brief physician-led conversations on the safety and efficacy of vaccines could drastically reduce vaccine-hesitancy. Most importantly, Mr. Santoki learned how effective physician-led conversations on treatment could drastically affect patient care. This sparked Mr. Santoki’s interest in understanding how cost of care conversations on a national scale could reduce financial toxicity for patients. Since then, Mr. Santoki has published his work on vaccine hesitancy as a first-author in the North Carolina Medical Journal (NCMJ).
After graduating from Duke University, Mr. Santoki has been working as a research fellow at the National Institutes of Health (NIH). At the NIH, Mr. Santoki routinely shadows neurooncologists having cost of care discussions with terminal cancer patients. Through these conversations Mr. Santoki has seen how patients can make much more informed decisions about their care and plan personalized and affordable courses of treatment. Moreover, Mr. Santoki has also been exposed to the potential of personalized medicine while working in Dr. Claire Le Pichon’s lab. While in the Le Pichon lab, Mr. Santoki has been assisting a project characterizing a novel mouse model of a rare form of ALS. Mr. Santoki has also been working part-time at a biopharma venture capital firm investigating drug pricing for rare disease therapeutics. Both these experiences have sparked Mr. Santoki’s interest in translating personalized therapeutics and ensuring they are affordable for patients. In his free time Mr. Santoki enjoys reading, weightlifting, and running.
For his Fulbright-Nehru project, Mr. Santoki is travelling to medical centers throughout Kerala to survey oncologists treating cancer patients. He is assessing physician awareness of treatment costs and low-cost alternatives. If time permits, Mr. Santoki aims to assess patients’ willingness to pay for genomic assays to define need for adjuvant chemotherapy for breast cancer. He is also estimating the proportion of patients who get colitis after starting immunotherapy. These analyses will help physicians determine whether cost conversations on preventative treatments can prevent future expenses.